ClinicalTrials.gg
Not yet recruitingNCT07940101Updated Nov 16, 2026

Clinical and Electrophysiological Heterogeneity in Adult Charcot-Marie-Tooth Disease

An observational study in Charcot-Marie-Tooth and Hereditary Peripheral Neuropathy, sponsored by Centre Hospitalier Universitaire de Nice. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Centre Hospitalier Universitaire de Nice · Observational

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Charcot-Marie-Tooth Disease with a site in France — 7 open to participants now, 11 under way, 2 of them phase 3. Charcot-Marie-Tooth Disease · France.

Started
2026
with 5 others
Observational
7 of 24
4 open now
Primary completion
2026-12
later than 2 of 10 live
Registered
24th of 24
by date
Lead sponsor
3 of 24
Centre Hospitalier Universitaire de Nice

Among the 24 studies in Charcot-Marie-Tooth Disease with a site in France, this one is one of 6 that started in 2026, is one of 7 observational ones, reaches primary completion later than 2 of the 10 other live ones, and was the 24th registered.

Charcot-Marie-Tooth Disease

114 studies on the registry are indexed under Charcot-Marie-Tooth Disease; 38 are open to participants now.

Browse Charcot-Marie-Tooth Disease studies →

Open to participants now

7 of the 24 studies in Charcot-Marie-Tooth Disease with a site in France are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 31 Charcot-Marie-Tooth Disease studies recruiting now, 14 (45%) set no upper age limit and 13 (42%) stop at 75 or younger; 14 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Charcot-Marie-Tooth Disease with a site in France, or all of them as a file.
02

Study summary

CMT-PROFILE is a single-center, cross-sectional observational study involving adults with Charcot-Marie-Tooth disease (CMT). The study will investigate the association between clinical disease severity, measured using the CMT Examination Score version 2 (CMTES-v2), and motor electrophysiological parameters, including compound muscle action potential (CMAP) amplitudes and motor nerve conduction velocities. Secondary objectives include characterizing clinical-electrophysiological concordance, comparing functional capacity, muscle strength and mobility across concordance groups, and exploring demographic, clinical, biological and genetic factors associated with variability in disease expression. Approximately 250 patients are planned for inclusion. All assessments will be performed at a single reference time point (M0), with no longitudinal follow-up.

03

Conditions studied

  • Charcot-Marie-Tooth
  • Hereditary Peripheral Neuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with Charcot-Marie-Tooth disease evaluated at the Peripheral Neuromuscular Rare Disease Reference Center of Nice University Hospital. The study aims to characterize the relationships between clinical disease severity, assessed using the CMTES-v2, motor electrophysiological parameters, and functional capacity. Participants will undergo a single reference assessment (M0), with no subsequent follow-up. The planned sample size is approximately 250 participants, subject to confirmation against the approved protocol.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 years or older.
  • Diagnosis of peripheral sensory polyneuropathy.
  • Classification as length-dependent (LDN) or non-length-dependent (NLDN) based on clinical and electrophysiological findings.
  • Available nerve conduction study including sural and radial sensory nerve amplitudes allowing calculation of the SRAR.
  • Evaluated at the Peripheral Neuromuscular Rare Disease Reference Center, Nice University Hospital, between January 2013 and July 2026.

Exclusion criteria

Exclusion Criteria:

  • Missing or incomplete clinical or electrophysiological data preventing SRAR calculation.
  • Unclassifiable neuropathy phenotype.
  • Technical factors affecting the reliability of nerve conduction studies.
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adults with Charcot-Marie-Tooth Disease

    Other: No intervention

Interventions

  • OtherNo intervention

    This observational, cross-sectional study evaluates clinical severity, electrophysiological parameters, and functional capacity in adults with Charcot-Marie-Tooth disease (CMT). Data collected at a single reference time point (M0) include the CMT Examination Score version 2 (CMTES-v2), nerve conduction study parameters, including compound muscle action potential (CMAP) amplitudes and motor nerve conduction velocities, and available functional and clinical measures. Additional variables may include muscle strength, mobility, pain, patient-perceived disease severity, occupational impact, and demographic, clinical, and genetic characteristics, as specified in the study protocol. No study-specific treatment or intervention is administered. There is no longitudinal follow-up

06

What researchers measure

Primary outcomes

  1. Association Between CMTES-v2 and Motor Electrophysiological Parameters

    To assess the association between the CMTES-v2 total score and prespecified motor electrophysiological parameters, including distal CMAP amplitudes and motor nerve conduction velocities, using correlation analyses as specified in the statistical analysis plan.

    Time frame: At day 0 (single assessment; no follow-up).

Secondary outcomes

  1. Clinical-Electrophysiological Concordance and Discordance Classification

    disease severity and electrophysiological impairment, using standardized residuals derived from the difference between observed CMTES-v2 scores and scores predicted from motor electrophysiological parameters, divided by the residual standard deviation. Patients will be classified into three mutually exclusive categories: concordant (standardized residual between -1.96 and +1.96), greater clinical severity than predicted (standardized residual above +1.96), or lower clinical severity than predicted (standardized residual below -1.96). Results will be expressed as the number and percentage of patients in each category.

    Time frame: At Day 0 (single assessment; no follow-up).

  2. Age at Assessment Across Clinical-Electrophysiological Concordance Groups

    To investigate whether age at clinical assessment differs according to the degree of clinical-electrophysiological concordance, age will be recorded in years and compared across the three predefined concordance groups.

    Time frame: At Day 0 (single assessment; no follow-up)

  3. Age at Symptom Onset Across Clinical-Electrophysiological Concordance Groups

    To investigate whether age at clinical assessment differs according to the degree of clinical-electrophysiological concordance, age will be recorded in years and compared across the three predefined concordance groups.

    Time frame: At Day 0 (single assessment; no follow-up)

  4. Disease Duration Across Clinical-Electrophysiological Concordance Groups

    To evaluate the relationship between disease duration and clinical-electrophysiological concordance, disease duration will be calculated as the interval, expressed in years, between the reported onset of symptoms and the reference clinical assessment. Disease duration will be compared across the three predefined concordance groups.

    Time frame: At Day 0 (single assessment; no follow-up)

  5. Genetic Subtype Distribution Across Clinical-Electrophysiological Concordance Groups

    To investigate whether the distribution of genetically confirmed Charcot-Marie-Tooth disease subtypes differs according to clinical-electrophysiological concordance, genetic subtypes documented in the medical records will be categorized and compared across the three predefined concordance groups. Results will be reported as the number and percentage of patients within each genetic subtype among those with available genetic data.

    Time frame: At Day 0 (single assessment; no follow-up)

  6. Functional Performance Across Clinical-Electrophysiological Concordance Groups (CMT-FOM)

    To evaluate whether functional performance differs according to clinical-electrophysiological concordance, functional capacity will be quantified using the total score of the Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM). Scores will be compared across the three predefined concordance groups among patients with available assessments.

    Time frame: At Day 0 (single assessment; no follow-up).

  7. Muscle Strength Across Clinical-Electrophysiological Concordance Groups (MRC Scale)

    To assess differences in muscle strength according to clinical-electrophysiological concordance, muscle strength will be evaluated using the Medical Research Council (MRC) grading scale, ranging from 0 (no visible or palpable muscle contraction) to 5 (normal muscle strength). Recorded muscle strength grades will be compared across the three predefined concordance groups.

    Time frame: At Day 0 (single assessment; no follow-up)

  8. Right Handgrip Strength Across Clinical-Electrophysiological Concordance Groups

    To assess differences in right handgrip strength according to clinical-electrophysiological concordance, right handgrip strength will be measured by dynamometry, with the highest value obtained from three trials retained for analysis. Measurements will be compared across the three predefined concordance groups.

    Time frame: At Day 0 (single assessment; no follow-up)

  9. Left Handgrip Strength Across Clinical-Electrophysiological Concordance Groups

    To assess differences in left handgrip strength according to clinical-electrophysiological concordance, left handgrip strength will be measured by dynamometry, with the highest value obtained from three trials retained for analysis. Measurements will be compared across the three predefined concordance groups.

    Time frame: At Day 0 (single assessment; no follow-up).

  10. Functional Mobility Across Clinical-Electrophysiological Concordance Groups (Timed Up and Go)

    To investigate differences in functional mobility according to clinical-electrophysiological concordance, mobility will be assessed using the Timed Up and Go (TUG) test, measuring the time required to rise from a chair, walk three meters, turn, return to the chair and sit down. Completion time will be recorded in seconds and compared across the three predefined concordance groups. Inability to complete the test safely will be recorded as a non-feasible assessment rather than assigned an arbitrary completion time.

    Time frame: At Day 0 (single assessment; no follow-up)

  11. Pain Intensity Across Clinical-Electrophysiological Concordance Groups

    To investigate whether pain intensity differs according to clinical-electrophysiological concordance, average pain intensity over the preceding seven days will be assessed using an 11-point numerical rating scale, ranging from 0 (no pain) to 10 (worst imaginable pain). Pain scores will be compared across the three predefined concordance groups.

    Time frame: At Day 0 (single assessment; no follow-up).

  12. Patient-Perceived Disease Severity Across Clinical-Electrophysiological Concordance Groups

    To evaluate differences in patient-perceived disease severity according to clinical-electrophysiological concordance, overall disease severity will be self-rated using a five-point ordinal scale ranging from 1 (very mild) to 5 (very severe). Scores will be compared across the three predefined concordance groups.

    Time frame: At Day 0 (single assessment; no follow-up)

  13. Work Absenteeism Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)

    To investigate differences in work absenteeism associated with Charcot-Marie-Tooth disease according to clinical-electrophysiological concordance, absenteeism will be assessed using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) and quantified as the percentage of working time missed due to the disease during the preceding seven days, ranging from 0% to 100%. Comparisons will be performed across the three predefined concordance groups among employed participants for whom the measure is applicable.

    Time frame: At Day 0 (single assessment; no follow-up)

  14. Work Presenteeism Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)

    To investigate differences in work-related productivity impairment while present at work according to clinical-electrophysiological concordance, presenteeism will be assessed using the WPAI:SHP questionnaire and expressed as the percentage of impairment while working attributable to Charcot-Marie-Tooth disease during the preceding seven days, ranging from 0% to 100%. Results will be compared across the three predefined concordance groups among participants for whom the measure is applicable.

    Time frame: At Day 0 (single assessment; no follow-up).

  15. Overall Work Productivity Impairment Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)

    To assess whether overall work productivity impairment differs according to clinical-electrophysiological concordance, overall impairment will be calculated from the absenteeism and presenteeism components of the WPAI:SHP questionnaire and expressed as a percentage ranging from 0% (no impairment) to 100% (complete impairment) over the preceding seven days. Results will be compared across the three predefined concordance groups among participants for whom the measure is applicable

    Time frame: At Day 0 (single assessment; no follow-up).

  16. Daily Activity Impairment Across Clinical-Electrophysiological Concordance Groups (WPAI:SHP)

    To assess differences in the impact of Charcot-Marie-Tooth disease on usual daily activities according to clinical-electrophysiological concordance, activity impairment will be quantified using the WPAI:SHP questionnaire and expressed as a percentage ranging from 0% (no impairment) to 100% (complete impairment) over the preceding seven days. Results will be compared across the three predefined concordance groups, irrespective of employment status

    Time frame: At Day 0 (single assessment; no follow-up)

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2026, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2026
First posted
Nov 16, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 31, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07940101
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Angela Puma
Contact
puma.ar@chu-nice.fr
0492035435 ext. +33
Abderhmane Slioui
Contact
slioui.a@chu-nice.fr
0492038953 ext. +33
Angela Puma
principal investigator · Centre Hospitalier Universitaire de Nice

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion